You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations
|
|---|---|
| Published in |
BMC Medicine, December 2015
|
| DOI | 10.1186/s12916-015-0539-5 |
| Pubmed ID | |
| Authors |
Valentine Duru, Nimol Khim, Rithea Leang, Saorin Kim, Anais Domergue, Nimol Kloeung, Sopheakvatey Ke, Sophy Chy, Rotha Eam, Chanra Khean, Kaknika Loch, Malen Ken, Dysoley Lek, Johann Beghain, Frédéric Ariey, Philippe J. Guerin, Rekol Huy, Odile Mercereau-Puijalon, Benoit Witkowski, Didier Menard |
| Abstract |
The declining efficacy of dihydroartemisinin-piperaquine against Plasmodium falciparum in Cambodia, along with increasing numbers of recrudescent cases, suggests resistance to both artemisinin and piperaquine. Available in vitro piperaquine susceptibility assays do not correlate with treatment outcome. A novel assay using a pharmacologically relevant piperaquine dose/time exposure was designed and its relevance explored in retrospective and prospective studies. The piperaquine survival assay (PSA) exposed parasites to 200 nM piperaquine for 48 hours and monitored survival 24 hours later. The retrospective study tested 32 culture-adapted, C580Y-K13 mutant parasites collected at enrolment from patients treated with a 3-day course of dihydroartemisinin-piperaquine and having presented or not with a recrudescence at day 42 (registered ACTRN12615000793516). The prospective study assessed ex vivo PSA survival rate alongside K13 polymorphism of isolates collected from patients enrolled in an open-label study with dihydroartemisinin-piperaquine for uncomplicated P. falciparum malaria in Cambodia (registered ACTRN12615000696594). All parasites from recrudescent cases had in vitro or ex vivo PSA survival rates ≥10 %, a relevant cut-off value for piperaquine-resistance. Ex vivo PSA survival rates were higher for recrudescent than non-recrudescent cases (39.2 % vs. 0.17 %, P <1 × 10(-7)). Artemisinin-resistant K13 mutants with ex vivo PSA survival rates ≥10 % were associated with 32-fold higher risk of recrudescence (95 % CI, 4.5-224; P = 0.0005). PSA adequately captures the piperaquine resistance/recrudescence phenotype, a mainstay to identify molecular marker(s) and evaluate efficacy of alternative drugs. Combined ex vivo PSA and K13 genotyping provides a convenient monitor for both artemisinin and piperaquine resistance where dihydroartemisinin-piperaquine is used. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 13% |
| Unknown | 7 | 88% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 137 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Vietnam | 1 | <1% |
| Unknown | 135 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 26 | 19% |
| Student > Master | 24 | 18% |
| Student > Ph. D. Student | 21 | 15% |
| Student > Doctoral Student | 11 | 8% |
| Student > Bachelor | 11 | 8% |
| Other | 23 | 17% |
| Unknown | 21 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 33 | 24% |
| Agricultural and Biological Sciences | 22 | 16% |
| Medicine and Dentistry | 18 | 13% |
| Immunology and Microbiology | 10 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 7% |
| Other | 17 | 12% |
| Unknown | 27 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2020.
All research outputs
#5,112,826
of 25,345,468 outputs
Outputs from BMC Medicine
#2,389
of 3,987 outputs
Outputs of similar age
#80,389
of 403,659 outputs
Outputs of similar age from BMC Medicine
#28
of 48 outputs
Altmetric has tracked 25,345,468 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,987 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.6. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 403,659 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.